Summary
Population-wide genomic screening (PGS) for Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, and Familial Hypercholesterolemia offers great promise in identifying the 1-2% of the population that unknowingly carries a pathogenic variant that puts them at elevated risk for serious, yet preventable disease. Rapidly decreasing sequencing costs, endorsement of PGS by national bodies, and attention to precision medicine applications have rapidly accelerated the spread of PGS programs. To date, no clear guidelines or implementation strategies exist to support the rapid growth of PGS. Co
